Posted by Michael Wonder on 28 Apr 2018
Meeting highlights - CHMP 23-26 April 2018 meeting
27 April 2018 - Three medicines recommended for approval.
The CHMP recommended granting a marketing authorisation for Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide), for the treatment of HIV-1 infection.
One hybrid medicine, Dzuveo (sufentanil) received a positive opinion for the treatment of pain. Hybrid applications rely in part on the results of pre-clinical tests and clinical trials for a reference product and in part on new data.
